CARMAT Appoints Eric Richez to Director of Business Development

Regulatory News:

CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart project, aiming to provide a therapeutic alternative for people suffering from end-stage heart failure, has strengthened its management team by appointing Mr. Eric Richez as Director of Business Development.

Eric’s first task will be to define CARMAT’s market access strategy. He will be working closely with the Medical department to manage the Company’s relationships with its investigation centers and to develop training centers. Working with senior management and the Marketing department, he will contribute to the planning and execution of reimbursement and marketing strategies.

According to Eric, "CARMAT’s artificial heart project is currently the most technologically advanced. This autoregulated bioprosthesis aims at offering major improvements compared to the available alternatives and therefore could appeal to the large group of patients who currently have no satisfying therapeutic solution.”

Eric Richez (53 years) has been working his entire career in the medical device industry in Europe in various sales, marketing and business development positions and in particular in the circulatory assist market. He spent 13 years in various sales and marketing positions at Thoratec, the market leader in ventricular assist devices. At Thoratec he served as the company’s Director of Sales & Marketing for Europe from 2002 to 2011 and was appointed Director of Sales for the EMEA region in 2011. His most recent position was with Circulite, where he oversaw sales for southern Europe.

Marcello Conviti, CARMAT’s General Manager commented: "On behalf of all CARMAT’s teams, I wish to extend our warmest welcome to Eric. His arrival marks an important milestone for CARMAT and will allow us to build a strong foundation for our future development in Europe”.

Eric Richez has a degree in mathematics with further professional training in business management, sales and sales management.

About CARMAT: the world’s most advanced total artificial heart project

The only credible response for all cases of end-stage heart failure, which is a real public health issue: CARMAT’s aim is to be able to provide a response to a major public health issue associated with heart disease, the world’s leading cause of death: chronic and acute heart failure. Indeed, this disease currently affects over 20 million patients in Europe and the United States. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from end-stage heart failure.

The result of combining two types of unique expertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards^® heart valves, which are the most used in the world, and the technological expertise of Airbus Group, world aerospace leader.

Imitating the natural heart: given its size, the choice of structural materials and its innovative physiological functions, CARMAT’s total artificial heart could, assuming upcoming clinical trials are successful, potentially benefit the lives of tens of thousands of patients a year whilst ensuring there is no risk of rejection and providing them with an unparalleled quality of life.

A project leader acknowledged at a European level: with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by Bpifrance; a total of €33 million.

Strongly committed, prestigious founders and shareholders: Airbus Group, Professor Alain Carpentier, the Centre Chirurgical Marie Lannelongue, Truffle Capital, a leading European venture capital firm, and the thousands of institutional and individual shareholders who have placed their trust in CARMAT.

For more information: www.carmatsa.com

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in CARMAT ("the Company") in any country. This press release contains forward-looking statements that relate to the Company’s objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company’s management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. The Company’s objectives as mentioned in this press release may not be achieved for any of these reasons or due to other risks and uncertainties.

No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the Document de Référence filed with the Autorité des Marchés Financiers under number D.14-045 on March 17, 2014 and the Note d’Opération that was approved with visa no. 11-308 on July 11, 2011, changes in economic conditions, the financial markets or the markets in which Carmat operates. In particular, no guarantee can be given concerning the Company’s ability to finalize the development, validation and industrialization of the prosthesis and the equipment required for its use, to manufacture the prostheses, satisfy the requirements of the ANSM, enroll patients, obtain satisfactory clinical results, perform the clinical trials and tests required for CE marking and to obtain the CE mark.

Name: CARMAT
ISIN code: FR0010907956
Ticker: ALCAR